Capital Impact Advisors, LLC Puma Biotechnology, Inc. Transaction History

Capital Impact Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 17, 2020	SELL	$7.01 - $13.24 $1.03 Million - $1.95 Million	-147,303 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$6.28 - $14.57 $53,844 - $124,923	8,574 Added 6.18%	147,303 $1.24 Million
Q4 2019 Feb 13, 2020	SELL	$6.5 - $10.73 $233,428 - $385,335	-35,912 Reduced 20.56%	138,729 $1.21 Million
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $416,605 - $611,814	47,612 Added 37.48%	174,641 $1.95 Million
Q2 2019 Jul 19, 2019	BUY	$12.3 - $35.76 $653,781 - $1.9 Million	53,153 Added 71.95%	127,029 $1.62 Million
Q4 2018 Mar 08, 2019	BUY	$20.07 - $46.7 $695,766 - $1.62 Million	34,667 Added 88.42%	73,876 $1.56 Million
Q3 2018 Oct 19, 2018	BUY	$41.2 - $59.85 $119,974 - $174,283	2,912 Added 8.02%	39,209 $1.8 Million
Q2 2018 Jul 25, 2018	BUY	$48.3 - $68.25 $486,284 - $687,141	10,068 Added 38.38%	36,297 $2.05 Million
Q1 2018 Apr 11, 2018	BUY	$59.7 - $99.25 $675,804 - $1.12 Million	11,320 Added 75.93%	26,229 $1.79 Million
Q3 2017 Jan 16, 2018	BUY	$72.0 - $119.75 $1.07 Million - $1.79 Million	14,909	14,909 $1.79 Million

100

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $135M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.